ERBB2 and breast cancer: Recent findings indicate that HER2+ BC that became unresponsive to anti-HER2 mAbs had developed an immunosuppressive phenotype during treatment, thereby supporting the importance of stimulating anti-tumor immunity in patients treated with anti-HER2 mAbs7.